Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic α3 β-tetrapeptides

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7836-7846

  Olsen, Christian A ^a   Ghadiri, M Reza ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; TETRAPEPTIDE;

ANIMAL CELL; ARTICLE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

CELL PROLIFERATION; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DISCOVERY; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; ISOENZYMES; JURKAT CELLS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OLIGOPEPTIDES; PEPTIDES, CYCLIC; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 72249094958     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900850t     Document Type: Article

References (91)

1. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693-705.
2. Allis, C. D.; Berger, S. L.; Cote, J.; Dent, S.; Jenuwien, T.; Kouzarides, T.; Pillus, L.; Reinberg, D.; Shi, Y.; Shiekhattar, R.; Shilatifard, A.; Workman, J.; Zhang, Y. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131, 633-636.
3. Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics - an epicenter of gene regulation: histones and histone-modifying enzymes. Angew. Chem., Int. Ed. 2005, 44, 3186-3216. (Pubitemid 40778337)
4. Verdin, E.; Dequiedt, F.; Kasler, H. G. Class II histone deacetylases: versatile regulators. Trends Genet. 2003, 19, 286-293.
5. Yuan, Z. L.; Guan, Y. J.; Chatterjee, D.; Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307, 269-273.
6. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X. F.; Yao, T. P. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417, 455-458.
7. Parmigiani,R.B.;Xu,W. S.;Venta-Perez, G.; Erdjument-Bromage, H.; Yaneva, M.; Tempst, P.; Marks, P. A. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 9633-9638.
8. Pandey, U. B.; Nie, Z.; Batlevi, Y.; McCray, B. A.; Ritson, G. P.; Nedelsky, N. B.; Schwartz, S. L.; DiProspero, N. A.; Knight, M. A.; Schuldiner, O.; Padmanabhan, R.; Hild, M.; Berry, D. L.; Garza, D.; Hubbert, C. C.; Yao, T. P.; Baehrecke, E. H.; Taylor, J. P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447, 859-863.
9. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic. J. Med. Chem. 2008, 51, 1505-1529.
10. Bieliauskas, A. V.; Pflum, M. K. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 2008, 37, 1402-1413.
11. Cole, P. A. Chemical probes for histone-modifying enzymes. Nat. Chem. Biol. 2008, 4, 590-597.
12. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769-784.
13. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38-51.
14. Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
15. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
16. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25, 84-90.
17. Kazantsev, A. G.; Thompson, L. M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug. Discovery 2008, 7, 854-868.
18. Fischer, A.; Sananbenesi, F.; Wang, X.; Dobbin, M.; Tsai, L. H. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447, 178-182.
19. Herman, D.; Jenssen, K.; Burnett, R.; Soragni, E.; Perlman, S. L.; Gottesfeld, J. M. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2006, 2, 551-558.
20. Tsankova, N. M.; Berton, O.; Renthal, W.; Kumar, A.; Neve, R. L.; Nestler, E. J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9, 519-525.
21. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
22. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B. C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12, 1325-1334.
23. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 15064-15069.
24. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N. P.; Lewis, T. A.; Maglathin, R. L.; McLean, T. H.; Bochkarev, A.; Plotnikov, A. N.; Vedadi, M.; Arrowsmith, C. H.HumanHDAC7harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 2008, 283, 11355-11363.
25. Bottomley,M. J.; Lo Surdo, P.; Di Giovine, P.; Cirillo,A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkuhler, C.; Gallinari, P.; Carfi, A. Structural and functional analysis of the humanHDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 2008, 283, 26694-26704.
26. Fischle, W.; Dequiedt, F.; Hendzel, M. J.; Guenther, M. G.; Lazar, M. A.; Voelter, W.; Verdin, E. Enzymatic activity associated with class IIHDACsis dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 2002, 9, 45-57. (Pubitemid 34127770)
27. Fischle, W.; Dequiedt, F.; Fillion, M.; Hendzel, M. J.; Voelter, W.; Verdin, E. Human HDAC7 histone deacetylase activity is associated withHDAC3in vivo. J. Biol. Chem. 2001, 276, 35826-35835.
28. Lahm, A.; Paolini, C.; Pallaoro, M.; Nardi, M. C.; Jones, P.; Neddermann, P.; Sambucini, S.; Bottomley, M. J.; Lo Surdo, P.; Carfi, A.; Koch, U.; De Francesco, R.; Steinkuhler, C.; Gallinari, P. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 17335-17340.
29. Vega, R. B.; Matsuda, K.; Oh, J.; Barbosa, A. C.; Yang, X.; Meadows, E.;McAnally, J.; Pomajzl, C.; Shelton, J.M.; Richardson, J. A.; Karsenty, G.; Olson, E. N. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119, 555-566.
30. Chang, S.; Young, B. D.; Li, S.; Qi, X.; Richardson, J. A.; Olson, E. N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126, 321-334.
31. Tao, R.; de Zoeten, E. F.; Ozkaynak, E.; Chen, C.; Wang, L.; Porrett, P. M.; Li, B.; Turka, L. A.; Olson, E. N.; Greene, M. I.; Wells, A. D.; Hancock, W. W. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 2007, 13, 1299-1307.
32. Wang, S.; Li, X.; Parra, M.; Verdin, E.; Bassel-Duby, R.; Olson, E. N. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 7738-7743.
33. Schreiber, S. L., Kapoor, T.; Wess, G., Eds. Chemical Biology: From Small Molecules to Systems Biology and Drug Design;Wiley-VCH: Weinheim, 2007; Vol.2, 303 pp.
34. Taori, K.; Paul, V. J.; Luesch, H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J. Am. Chem. Soc. 2008, 130, 1806-1807.
35. Ying, Y.; Taori, K.; Kim, H.; Hong, J.; Luesch, H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J. Am. Chem. Soc. 2008, 130, 8455-8459.
36. Seiser, T.; Kamena, F.; Cramer, N. Synthesis and biological activity of largazole and derivatives. Angew. Chem., Int. Ed. 2008, 47, 6483-6485.
37. Bowers, A.; West, N.; Taunton, J.; Schreiber, S. L.; Bradner, J. E.; Williams, R. M. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J. Am. Chem. Soc. 2008, 130, 11219-11222.
38. Nasveschuk, C. G.; Ungermannova, D.; Liu, X.; Phillips, A. J. A concise total synthesis of largazole, solution structure, and some preliminary structure-activity relationships. Org. Lett. 2008, 10, 3595-3598.
39. Ghosh, A. K.; Kulkarni, S. Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase. Org. Lett. 2008, 10, 3907-3909.
40. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
41. Taunton, J.; Hassig, C. A.; Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272, 408-411.
42. Kawai, M.; Rich, D. H.; Walton, J. D. The structure and conformation of HC-toxin. Biochem. Biophys. Res. Commun. 1983, 111, 398-403.
43. Shute, R. E.; Dunlap, B.; Rich, D. H. Analogues of the cytostatic and antimitogenic agents chlamydocin and HC-toxin: synthesis and biological activity of chloromethyl ketone and diazomethyl ketone functionalized cyclic tetrapeptides. J. Med. Chem. 1987, 30, 71-78.
44. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R. W.; Dulski, P. M.; Crumley, T. M.; Allocco, J. J.; Cannova, C.; Meinke, P. T.; Colletti, S. L.; Bednarek, M. A.; Singh, S. B.; Goetz, M. A.; Dombrowski, A. W.; Polishook, J. D.; Schmatz, D. M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13143-13147.
45. Singh, S. B.; Zink, D. L.; Polishook, J. D.; Dombrowski, A. W.; Darkin-Rattray, S. J.; Schmatz, D. M.; Goetz, M. A. Apicidins: Novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum. Tetrahedron Lett. 1996, 37, 8077-8080.
46. Kranz, M.; Murray, P. J.; Taylor, S.; Upton, R. J.; Clegg, W.; Elsegood, M. R. Solution, solid phase and computational structures of apicidin and its backbone-reduced analogs. J. Pept. Sci. 2006, 12, 383-388.
47. Nakao, Y.; Yoshida, S.; Matsunaga, S.; Shindoh, N.; Terada, Y.; Nagai, K.; Yamashita, J. K.; Ganesan, A.; van Soest, R. W.; Fusetani, N.; Azumamides, A-E histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis. Angew. Chem., Int. Ed. 2006, 45, 7553-7557.
48. Izzo, I.; Maulucci, N.; Bifulco, G.; De Riccardis, F. Total synthesis of azumamides A and E. Angew. Chem., Int. Ed. 2006, 45, 7557-7560.
49. Maulucci, N.; Chini, M. G.; Micco, S. D.; Izzo, I.; Cafaro, E.; Russo, A.; Gallinari, P.; Paolini, C.; Nardi, M. C.; Casapullo, A.; Riccio, R.; Bifulco, G.; Riccardis, F. D. Molecular insights into azumamide E histone deacetylases inhibitory activity. J. Am. Chem. Soc. 2007, 129, 3007-3012.
50. Wen, S.; Carey, K. L.; Nakao, Y.; Fusetani, N.; Packham, G.; Ganesan, A. Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. Org. Lett. 2007, 9, 1105-1108.
51. Nakao, Y.; Narazaki, G.; Hoshino, T.; Maeda, S.; Yoshida, M.; Maejima, H.; Yamashita, J. K. Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg. Med. Chem. Lett. 2008, 18, 2982-2984.
52. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 87-92.
53. Meinke, P. T.; Colletti, S. L.; Doss, G.; Myers, R. W.; Gurnett, A. M.; Dulski, P. M.; Darkin-Rattray, S. J.; Allocco, J. J.; Galuska, S.; Schmatz, D. M.; Wyvratt, M. J.; Fisher, M. H. Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. J. Med. Chem. 2000, 43, 4919-4922.
54. Colletti, S. L.; Myers, R. W.; Darkin-Rattray, S. J.; Gurnett, A. M.; Dulski, P. M.; Galuska, S.; Allocco, J. J.; Ayer, M. B.; Li, C.; Lim, J.; Crumley, T. M.; Cannova, C.; Schmatz, D. M.; Wyvratt, M. J.; Fisher, M. H.; Meinke, P. T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Bioorg. Med. Chem. Lett. 2001, 11, 107-111.
55. Colletti, S. L.; Myers, R. W.; Darkin-Rattray, S. J.; Gurnett, A. M.; Dulski, P. M.; Galuska, S.; Allocco, J. J.; Ayer, M. B.; Li, C.; Lim, J.; Crumley, T. M.; Cannova, C.; Schmatz, D. M.; Wyvratt, M. J.; Fisher, M. H.; Meinke, P. T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Bioorg. Med. Chem. Lett. 2001, 11, 113-117.
56. Taunton, J.; Collins, J. L.; Schreiber, S. L. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J. Am. Chem. Soc. 1996, 118, 10412-10422.
57. Berst, F.; Ladlow, M.; Holmes, A. B. Solid-phase synthesis of apicidin A and a cyclic tetrapeptoid analogue. Chem. Commun. 2002, 508-509.
58. Shivashimpi, G. M.; Amagai, S.; Kato, T.; Nishino, N.; Maeda, S.; Nishino, T. G.; Yoshida, M. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg. Med. Chem. 2007, 15, 7830-7839.
59. Gomez-Paloma, L.; Bruno, I.; Cini, E.; Khochbin, S.; Rodriquez, M.; Taddei, M.; Terracciano, S.; Sadoul, K. Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222. ChemMedChem 2007, 2, 1511-1519.
60. Horne, W. S.; Olsen, C. A.; Beierle, J. M.; Montero, A.; Ghadiri, M. R. Probing the bioactive conformation of an archetypal natural product HDAC inhibitor with conformationally homogeneous triazole-modified cyclic tetrapeptides. Angew. Chem., Int. Ed. 2009, 48, 4718-4724.
61. Ying, Y.; Liu, Y.; Byeon, S. R.; Kim, H.; Luesch, H.; Hong, J. Synthesis and activity of largazole analogues with linker and macrocycle modification. Org. Lett. 2008, 10, 4021-4024.
62. Bowers, A. A.; Greshock, T. J.; West, N.; Estiu, G.; Schreiber, S. L.; Wiest, O.; Williams, R. M.; Bradner, J. E. Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole. J. Am. Chem. Soc. 2009, 131, 2900-2905.
63. Bowers, A. A.; West, N.; Newkirk, T. L.; Troutman-Youngman, A. E.; Schreiber, S. L.; Wiest, O.; Bradner, J. E.; Williams, R. M. Synthesis and histone deacetylase inhibitory activity of largazole 7846 Journal of Medicinal Chemistry, 2009, Vol.52, No.23 Olsen and Ghadiri analogs: alteration of the zinc-binding domain and macrocyclic scaffold. Org. Lett. 2009, 11, 1301-1304.
64. Schumann, F.; Muller, A.; Koksch, M.; Muller, G.; Sewald, N. Are beta-amino acids gamma-turn mimetics? Exploring a new design principle for bioactive cyclopeptides. J. Am. Chem. Soc. 2000, 122, 12009-12010.
65. Glenn, M. P.; Kelso, M. J.; Tyndall, J. D.; Fairlie, D. P. Conformationally homogeneous cyclic tetrapeptides: useful new threedimensional scaffolds. J. Am. Chem. Soc. 2003, 125, 640-641.
66. Norgren, A. S.; Buttner, F.; Prabpai, S.; Kongsaeree, P.; Arvidsson, P. I. Beta2-amino acids in the design of conformationally homogeneous cyclo-peptide scaffolds. J. Org. Chem. 2006, 71, 6814-6821.
67. Montero, A.; Beierle, J. M.; Olsen, C. A.; Ghadiri, M. R. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/betatetrapeptide architectures. J. Am. Chem. Soc. 2009, 131, 3033-3041.
68. Lam, K. S.; Salmon, S. E.; Hersh, E. M.; Hruby, V. J.; Kazmierski, W. M.; Knapp, R. J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991, 354, 82-84.
69. Yang,W.M.; Tsai, S. C.;Wen, Y. D.; Fejer, G.; Seto, E. Functional domains of histone deacetylase-3. J. Biol.Chem. 2002, 277, 9447-9454.
70. Glenn, M. P.; Kahnberg, P.; Boyle, G. M.; Hansford, K. A.; Hans, D.; Martyn, A. C.; Parsons, P. G.; Fairlie, D. P. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. J. Med. Chem. 2004, 47, 2984-2994.
71. Simon, M. D.; Chu, F.; Racki, L. R.; de la Cruz, C. C.; Burlingame, A. L.; Panning, B.; Narlikar, G. J.; Shokat, K. M. The site-specific installation of methyl-lysine analogs into recombinant histones. Cell 2007, 128, 1003-1012.
72. Krennhrubec, K.; Marshall, B. L.; Hedglin, M.; Verdin, E.; Ulrich, S. M. Design and evaluation of "Linkerless" hydroxamic acids as selective HDAC8 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 2874-2878.
73. Kahnberg, P.; Lucke, A. J.; Glenn, M. P.; Boyle, G. M.; Tyndall, J. D.; Parsons, P. G.; Fairlie, D. P. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J. Med. Chem. 2006, 49, 7611-7622.
74. Redman, J. E.; Wilcoxen, K. M.; Ghadiri, M. R. Automated mass spectrometric sequence determination of cyclic peptide library members. J. Comb. Chem. 2003, 5, 33-40.
75. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Butcher, R. A.; Schreiber, S. L. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 2003, 10, 383-396.
76. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4389-4394.
77. Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem. 2008, 51, 2898-2906.
78. Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem. 2006, 49, 4809-4812.
79. Itoh, Y.; Suzuki, T.; Kouketsu, A.; Suzuki,N.;Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Design, synthesis, structureselectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J. Med. Chem. 2007, 50, 5425-5438.
80. Heltweg, B.; Dequiedt, F.; Marshall, B. L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M. Subtype selective substrates for histone deacetylases. J. Med. Chem. 2004, 47, 5235-5243.
81. 50 = 343 nM), which further confirmed the HDAC8/HDAC6 selectivity for compound 23.
82. Kozikowski, A. P.; Tapadar, S.; Luchini, D. N.; Kim, K. H.; Billadeau, D. D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem. 2008, 51, 4370-4373.
83. Gurard-Levin, Z. A.; Mrksich, M. The activity ofHDAC8depends on local and distal sequences of its peptide substrates. Biochemistry 2008, 47, 6242-6250. (Pubitemid 351812837)
84. Chou, C. J.; Herman, D.; Gottesfeld, J. M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem. 2008, 283, 35402-35409.
85. Wegener, D.; Hildmann, C.; Riester, D.; Schwienhorst, A. Improved fluorogenic histone deacetylase assay for high-throughput screening applications. Anal. Biochem. 2003, 321, 202-208.
86. Salisbury, C. M.; Cravatt, B. F. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 1171-1176.
87. Salisbury, C. M.; Cravatt, B. F. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J. Am. Chem. Soc. 2008, 130, 2184-2194.
88. Lam, K. S.; Lebl, M.; Krchnak, V. The "One-bead-one - compound" combinatorial library method. Chem. Rev. 1997, 97, 411-448.
89. Dartois, V.; Sanchez-Quesada, J.; Cabezas, E.; Chi, E.; Dubbelde, C.; Dunn, C.; Granja, J.; Gritzen, C.; Weinberger, D.; Ghadiri, M. R.; Parr, T. R., Jr. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 2005, 49, 3302-3310.
90. Horne, W. S.; Wiethoff, C. M.; Cui, C.; Wilcoxen, K. M.; Amorin, M.; Ghadiri, M. R.; Nemerow, G. R. Antiviral cyclic D,L-alphapeptides: targeting a general biochemical pathway in virus infections. Bioorg. Med. Chem. 2005, 13, 5145-5153.
91. Fletcher, J. T.; Finlay, J. A.; Callow, M. E.; Callow, J. A.; Ghadiri, M. R. A combinatorial approach to the discovery of biocidal sixresidue cyclic D,L-alpha-peptides against the bacteria methicillinresistant Staphylococcus aureus (MRSA) and E. coli and the biofouling algae Ulva linza and Navicula perminuta. Chem. - Eur. J. 2007, 13, 4008-4013.